Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

ANI Pharmaceuticals ($ANIP) announced the acquisition of Inderal® XL from Cranford Pharmaceuticals, LLC and InnoPran XL® from Holmdel Pharmaceuticals LP. As a part of the deals, the company acquired the NDA and trademark for InnoPran XL® including a license to an Orange Book listed patent, and a distribution license and trademark for Inderal® XL as well as finished goods inventory of both products. Both the drugs are available in 80mg and 120mg sustained release capsules and are indicated for hypertension.
The company will start selling both the products with immediate effect. ANI Pharmaceuticals stock has gained more than 76 percent in the past 12 months.

La Jolla Pharmaceuticals ($LJPC) stock shot up over 76 percent in its Monday trading session as the company reported a phase 3 trial update for its hypotension drug, LJPC-501. The results showed extreme efficacy, cutting mortality risk by nearly a quarter after 28 days. Of 163 patients, 70% demonstrated a blood pressure response vs. 23% of 158 placebo-treated patients. The company also reported that nearly nine in 10 critically ill patients treated with LJPC-501 (87%) experienced at least one adverse event vs. 92% of placebo-treated patients.
La Jolla stock price is now up 121 percent in the past 12 months while its Year to Date gain stands at 100 percent.

 

• Pfizer Inc. ($PFE) announced that it has received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients. In a regulatory filing on Thursday, Pfizer said the December 2015 and July 2016 subpoenas were related to groups that help cover patient co-payments for prescription drugs.
• Incyte Corporation ($INCY) will join the S&P 500 index with effect from the open of trading this Tuesday. Spectra is leaving the S&P 500 given its pending acquisition by Canada-based Enbridge. Incyte specializes in oncology products and will be added to the S&P 500's biotechnology sub-industry index, according to the release.

• OncoSec Medical ($ONCS) stock jumped as the company announced receiving Fast Track status from the FDA for its ImmunoPulse IL-12 for the treatment of metastatic melanoma following progression on pembrolizumab (Merck's KEYTRUDA) or nivolumab (Bristol-Myers Squibb's Opdivo). ImmunoPulse IL-12 delivers a pulsed electric field to cells via a hand-held applicator which temporarily increases the porosity of the cell membranes (electroporation). The Fast Track designation provides for more frequent interactions with the FDA review team and a rolling review of the NDA.
• HTG Molecular Diagnostics ($HTGM) stock jumped as the company announced that its new direct-target sequencing chemistry will be available in the company’s VERI/O laboratory as a service offering beginning in the first quarter of 2017. It is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company’s current HTG EdgeSeq chemistry applications.

 
• Valeant Pharmaceuticals ($VRX) announced its resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an intraocular pressure lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. The data in the application support latanoprostene bunod as the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use.
• Mead Johnson Nutrition Company ($MJN) announced that it has inked a new deal to acquire spray drying and finishing capabilities in Australia from Bega Cheese Limited (Bega), one of Australia’s leading dairy product companies. Bega has been a certified ingredient supplier for MJN products since 2009. The transaction is expected to close in the second quarter of 2017.

 
• Endo International Plc ($ENDP) reported its net loss for the fourth quarter at $3.34 billion, or $14.98 per share, up from $118.46 million, or $0.53 per share, a year earlier. The company took a $3.5 billion asset impairment charge in the latest quarter, related to its generics reporting unit. Endo reported its total revenue at $1.24 billion, up from $1.07 billion.
• Amarin Corporation Plc ($AMRN) reported its fourth quarter and annual results. The company earned total revenue of $130.1 million for the entire year, up 59 percent from the previous year. It increased gross margin on product sales to 73% in 2016, versus 66% in 2015, driven by improvements in product related costs.

Stephens Downgrades Halyard Health (HYH) Overweight -> Equal Weight

Morgan Stanley Reiterates Horizon Pharma PLC (HZNP)
Equal Weight
Mizuho Lowers Target Horizon Pharma PLC (HZNP)
$22.00
Cantor Fitzgerald Reiterates Allscripts Healthcare Solutions (MDRX)
Hold $13.00
HC Wainwright Reiterates OpGen (OPGN)
Buy $2.00
Canaccord Genuity Reiterates Perrigo Company plc (PRGO)
Buy $97.00

Gainers (% price change)Last TradeChangeMkt CapImmunoGen, Inc.IMGN3.28+0.57 (21.03%)297.32MVermillion, Inc.VRML2.40+0.30 (14.29%)123.68MAlnylam PharmaceuticalsALNY51.31+4.69 (10.06%)4.45BAcorda Therapeutics IncACOR27.40+2.50 (10.04%)1.26BCelldex Therapeutics, IncCLDX3.58+0.32 (9.82%)437.76MLosers (% price change)Magellan Health IncMGLN70.20-4.15 (-5.58%)1.51BHorizon Pharma PLCHZNP16.48-0.97 (-5.56%)2.76BOclaro, Inc.OCLR8.86-0.37 (-4.01%)1.43BNova MeasuringNVMI17.03-0.65 (-3.68%)461.66MCryolife IncCRY16.75-0.50 (-2.90%)574.06MMost Actives (dollar volume)Incyte CorporationINCY134.02+2.81 (2.14%)27.31BPfizer Inc.PFE34.28+0.02 (0.06%)209.24BJohnson & JohnsonJNJ122.40-0.33 (-0.27%)335.81BUnitedHealth Group IncUNH165.38+2.32 (1.42%)157.75BBristol-Myers Squibb CoBMY56.56+0.14 (0.25%)95.75B